STAT3 as a Potential Target for Tumor Suppressive Effects of 15-Deoxy-Δ12,14-prostaglandin J2 in Triple Negative Breast Cancer

김수정; Nam-Chul Cho; Young-Il Hahn; Seong-Hoon Kim; Xizhu Fang; 서영준

추천

검색

자료유형: 학술저널

저자정보: 김수정 (서울대학교) Nam-Chul Cho (Korea Research Institute of Chemical Technology) Young-Il Hahn (Seoul National University) Seong-Hoon Kim (Seoul National University) Xizhu Fang (Seoul National University) 서영준 (서울대학교)

저널정보: 대한암예방학회 대한암예방학회지 대한암예방학회지 제26권 제3호

발행연도: 2021.9

수록면: 207 - 217 (11page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

STAT3 plays a prominent role in proliferation and survival of tumor cells. Thus, STAT3 has been considered to be a prime target for development of anti-cancer therapeutics. The electrophilic cyclopentenone prostaglandin,15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) has been well recognized for its capability to modulate intracellular signaling pathways involved in cancer cell growth and progression. We previously reported that 15d-PGJ2 had potent cytotoxicity against harvey-ras transformed human mammary epithelial cells through direct interaction with STAT3. In this study, we have attempted to verify the inhibitory effects of 15d-PGJ2 on STAT3 signaling in human breast tumor cells. The triple negative breast cancer cell lines, MDA-MB-231 and MDA-MB-468 display ing constitutive phosphorylation of STAT3 on the tyrosine 705 (Tyr705) residue, underwent apoptosis upon inhibition of STAT3 by 15d-PGJ2. In contrast, estrogen receptor positive MCF-7 breast cancer cells that do not exhibit elevated STAT3 phosphorylation were much less susceptible to 15d-PGJ2-induced apoptosis as assessed by PARP cleavage. Furthermore, 15d-PGJ2 inhibited interleukin-6-induced tyrosine phosphorylation of STAT3 in LNCaP cells. According to molecular docking studies, 15d-PGJ2 may preferentially bind to the cysteine 259 residue (Cys259) present in the coiled-coil domain of STAT3. Site-directed mutagenesis of STAT3 identified Cys259 to be the critical amino acid for the 15d-PGJ2-induced apoptosis as well as epithelial-to-mesenchymal transition. Taken together, these findings suggest STAT3 inactivation through direct chemical modification of its Cys259 as a poten tial therapeutic approach for treatment of triple negative breast cancer treatment. Key Words Breast neoplasms, Cyclopentenone prostaglandin, 15-Deoxy-Δ12,14-prostaglandin J2, STAT3

#Breast neoplasms #Cyclopentenone prostaglandin #15-Deoxy-Δ12 #14-prostaglandin J2 #STAT3

참고문헌 (60)

참고문헌 신청

Bray F / 2018 / Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185countries / CA Cancer J Clin 68:394~424

Allemani C / 2015 / Global surveillance of cancer survival 1995-2009 : analysis of individual data for 25, 676, 887 patients from 279population-based registries in 67 countries(CONCORD-2) / Lancet 385:977~1010

Chia S / 2008 / Locally advanced and inflammatory breast cancer / J Clin Oncol 26:786~790

Forman BM / 1995 / 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma / Cell 83:803~812

Kliewer SA / 1995 / A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation / Cell 83:813~819

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!